Exploratory Research and Hypothesis in Medicine **2025** vol. 11(1) | e00034
DOI: 10.14218/ERHM.2025.00034

Review Article

The Applications of Artificial Intelligence in the Diagnosis and Treatment of Diseases in Soft Tissue: From Healthcare to Future Insights

Marwan Al-Raeei[1,2,3,4*]

[1]*Damascus University, Damascus, Syria;* [2]*International University for Science and Technology, Ghabagheb, Syria;* [3]*Al-Andalus University for Medical Sciences, Tartus, Syria;* [4]*Cordoba Private University, Aleppo, Syria*

Received: July 03, 2025 | **Revised:** October 08, 2025 | **Accepted:** November 03, 2025 | **Published online:** December 19, 2025

Abstract

Artificial intelligence (AI) is transforming the diagnosis, treatment, monitoring, and research of soft tissue disorders, which include muscles, tendons, ligaments, fascia, nerves, and blood vessels. Traditional diagnostic methods often rely on imaging, histopathology, and clinical evaluation, which can be time-consuming and prone to human error. This review aims to explore the impact of AI on enhancing soft tissue care. The review examines the application of deep learning algorithms in medical imaging, pathology, predictive analytics, and treatment planning. It also evaluates AI's role in monitoring and rehabilitation, as well as its contributions to research in soft tissue disorders. AI significantly improves the accuracy of medical imaging analysis, facilitating the detection of abnormalities such as tumors and tears. AI-powered pathology tools automate slide analysis, enhancing diagnostic consistency and efficiency. Predictive analytics enable early risk assessment and personalized patient management. In surgical contexts, AI supports preoperative simulations and robotic-assisted procedures, leading to improved outcomes. Additionally, AI enhances patient monitoring through wearable devices and telemedicine. The integration of AI into soft tissue diagnostics and therapeutics presents transformative potential for personalized and efficient healthcare. However, challenges related to data security, algorithm bias, interpretability, and ethical considerations must be addressed. Overall, AI holds promise for improving patient outcomes and advancing medical science in the field of soft tissue disorders.

Introduction

Soft tissues are the supportive structures within the body that include muscles, tendons, ligaments, fascia, nerves, and blood vessels.[1,2] In contrast to hard tissues like bone, which offer structural support and rigidity, soft tissues are characterized by their flexibility and are essential for various physiological functions such as movement, stabilization, and nourishment.[3] For instance, muscles generate the force required for movement, tendons connect muscles to bones, ligaments help stabilize joints, and fascia encases and supports muscles and organs.[4–6] These tissues can be susceptible to a variety of conditions, including injuries, infections, inflammatory diseases, and tumors, all of which can greatly affect an individual's health and well-being.[7,8]

The diagnosis of soft tissue disorders has traditionally relied on thorough clinical evaluations, imaging technologies, and histopathological analyses.[9–11] Medical imaging techniques such as magnetic resonance imaging (MRI),[12–14] computed tomography (CT),[15,16] and ultrasound are instrumental in visualizing soft tissue structures and identifying abnormalities.[17,18] However, interpreting these complex images requires a high degree of expertise and can be subject to human error. This is where advancements in artificial intelligence (AI) are making a profound impact.

AI technology, which has many applications in the field of medicine (illustrated in Fig. 1 from the Scopus database), particularly in the form of deep learning algorithms, is revolutionizing how clinicians diagnose soft tissue conditions.[19–22] By leveraging vast datasets of medical images and patient histories, AI systems can identify patterns and anomalies that might not be easily discernible to the human eye. This capability is particularly beneficial in emergency situations, where prompt and accurate diagnosis can be critical. For instance, AI algorithms can analyze MRI scans to detect soft tissue tumors with a level of precision that rivals, and in some cases exceeds, that of experienced radiologists. This has the potential not only to improve diagnostic

Keywords: Soft tissue; Artificial intelligence; AI; Healthcare; Treatment, Ethics; Robotic.

***Correspondence to:** Marwan Al-Raeei, Damascus University, Damascus 96311, Syria. ORCID: https://orcid.org/0000-0003-0984-2098. Tel: +963-947833522, E-mail: mhdm-ra@scs-net.org; mn41@live.com

How to cite this article: Al-Raeei M. The Applications of Artificial Intelligence in the Diagnosis and Treatment of Diseases in Soft Tissue: From Healthcare to Future Insights. *Explor Res Hypothesis Med* 2025;000(000):e00034. doi: 10.14218/ERHM.2025.00034.



Fig. 1. Flowchart illustrating various artificial intelligence challenges and issues encountered in the field of medicine.

accuracy but also to expedite treatment decisions, thereby enhancing patient outcomes.

Furthermore, AI is increasingly being incorporated into pathology, assisting in the interpretation of histopathological slides. Traditional tissue sample analysis under a microscope is often time-consuming and subject to variability. AI-powered computer vision methods can automate the identification of cancerous cells and other abnormalities, enabling pathologists to concentrate their efforts on the most critical areas. Incorporating AI into the diagnostic process can improve the consistency and efficiency of soft tissue diagnoses, ultimately supporting more effective treatment plans.

AI's role in diagnosing soft tissue disorders extends beyond imaging and pathology to include predictive analytics. By examining extensive datasets that encompass genetic information, lifestyle factors, and clinical outcomes, AI can help identify individuals at elevated risk for certain soft tissue diseases. This proactive approach allows healthcare providers to implement preventive strategies and customize monitoring, enhancing early detection and the chances of successful intervention.

As AI technology advances, its application in diagnosing soft tissue conditions becomes increasingly refined. Its integration promises not only to improve the accuracy of current diagnostic techniques but also to promote a more personalized approach to patient care. Through the analysis of complex data and the generation of actionable insights, AI supports clinicians in making well-informed decisions tailored to each patient's unique profile.

This review will explore the various ways AI is transforming the diagnosis of soft tissue disorders. The review will discuss advancements in medical imaging, the role of AI in pathology, and the potential of predictive analytics to facilitate early detection and intervention. By highlighting these developments, the review aims to demonstrate AI's significant contributions to soft tissue diagnosis and its broader impact on patient care and healthcare systems. The integration of AI into diagnostic processes represents a major leap forward in technology and underscores the importance of innovation in addressing the challenges associated with soft tissue disorders.

Methodology

This review synthesizes the current literature and recent advances in applying artificial intelligence to diagnose soft tissue disorders, guide treatment planning, monitor progress, support rehabilitation, and inform research directions. The presentation is concise and systematic, focusing on what was done and how the information was organized rather than enumerating every operational detail. Across imaging, pathology, predictive analytics, treatment planning, and rehabilitation, studies, clinical trials, and technological innovations were identified and summarized to reveal overarching patterns and gaps.

A targeted search of peer-reviewed journals and conference proceedings was conducted in multiple scientific databases. Search terms encompassed artificial intelligence, soft tissue disorders, medical imaging, pathology, predictive analytics, rehabilitation, and biomechanical analysis. Inclusion criteria prioritized AI applications directly related to diagnosing soft tissue disorders and the associated domains of imaging, pathology, predictive analytics, treatment planning, and rehabilitation, with publications in English. Exclusion criteria removed non-peer-reviewed works, editorials, opinion pieces, duplicates, and studies lacking sufficient data. Data extraction aimed to identify core findings, methodological approaches, and outcomes, organizing them thematically into imaging analysis, pathology, predictive analytics, treatment planning, monitoring and rehabilitation, and research and development.

To enrich perspective, expert consultations with clinicians and researchers in soft tissue disorders and AI applications were incorporated. These discussions provided practical context, validated ambiguous findings, and helped surface emerging trends not fully captured in the published literature. The approach acknowledges limitations, including potential publication bias wherein studies with favorable results are more likely to appear, and the accelerat-

ing pace of AI innovation, which means new evidence may emerge after the search window. Nonetheless, the review seeks to balance breadth with relevance, illuminating how AI is transforming diagnosis and management of soft tissue disorders. It also identifies concrete gaps, opportunities for standardization, and avenues for future research and development, with attention to clinical impact, safety, and reproducibility.

Data synthesis employed a narrative, thematically driven approach rather than a formal meta-analysis, given heterogeneity in study design, AI methods, and outcome measures. Findings were cross-walked across domains to identify which AI techniques most consistently support specific clinical questions, which imaging modalities benefit most from AI, and where evidence remains preliminary. The synthesis emphasized clinically meaningful endpoints such as diagnostic accuracy, decision-support impact, and functional outcomes, while acknowledging limitations, including small samples, retrospective designs, and variable external validation that may affect generalizability and applicability globally.

Diagnosis of soft tissues using AI technology

The diagnosis of soft tissue disorders has advanced considerably with the development of cutting-edge technologies, especially in medical imaging and pathology.[23,24] These innovations have improved diagnostic precision and facilitated better patient outcomes by enabling earlier detection and treatment.[25,26] A particularly groundbreaking advancement is the integration of AI, notably through deep learning algorithms. These tools are revolutionizing the way clinicians evaluate soft tissue abnormalities, including tumors, tears, and inflammatory conditions.

Medical imaging analysis

Medical imaging plays a pivotal role in diagnosing soft tissue conditions. Techniques such as MRI, CT scans, and ultrasounds are routinely used to visualize soft tissues in the body. Traditional interpretation of these images relies heavily on the expertise of radiologists, who examine the scans for any signs of abnormalities. However, the integration of AI algorithms into this process has introduced a new level of precision and efficiency.[27,28]

Deep learning models, a subset of AI, are particularly adept at analyzing vast amounts of imaging data. These models are trained on extensive datasets that include labeled images of both healthy and diseased tissues. As a result, they can learn to identify subtle patterns and features that may indicate the presence of soft tissue disorders. Research has shown that, in certain scenarios, these AI models can outperform human radiologists in detecting conditions such as tumors, tears, or signs of inflammation.[29,30] For example, in the case of soft tissue sarcomas, AI systems can analyze MRI images to pinpoint not only the presence of a tumor but also its specific characteristics, aiding in more accurate staging and treatment planning.[31–34]

Moreover, AI's ability to process images quickly allows for a reduction in the time required for diagnosis.[35,36] In emergency settings, where time is of the essence, the expedited analysis provided by AI can lead to faster identification of life-threatening conditions, thereby facilitating timely interventions.[37,38] As AI continues to advance, it is likely that its role in medical imaging will expand, potentially leading to more automated systems that support radiologists rather than replace them.[39,40]

Pathology

In addition to imaging, AI technologies are making significant strides in the field of pathology, particularly in the analysis of histopathological slides. Histopathology involves examining tissue samples under a microscope to identify abnormalities at the cellular level, a critical step in diagnosing soft tissue cancers and other disorders. Traditional methods of histopathological analysis are labor-intensive and subject to human error, which can lead to variances in diagnosis.

AI-driven computer vision techniques have been developed to automate the recognition of histological patterns and abnormalities in soft tissue samples.[41,42] These algorithms can analyze stained slides and pinpoint cancerous cells with remarkable accuracy.[43,44] By employing image segmentation and classification methods, AI can differentiate between benign and malignant tissues, assess tumor grade, and determine the stage of cancer, all of which are vital for effective treatment planning.[45,46]

Furthermore, the integration of AI in pathology can significantly enhance the efficiency of the diagnostic process. Pathologists often face large workloads, and the assistance of AI can help prioritize cases based on urgency or complexity.[47,48] By flagging slides that exhibit suspicious features for further review, AI allows pathologists to focus their expertise where it is most needed, ultimately improving diagnostic throughput and consistency.[49,50]

Additionally, the use of AI in pathology is not limited to cancer diagnosis. It can also assist in identifying inflammatory conditions, degenerative diseases, and infections affecting soft tissues. As AI technologies continue to evolve, they may provide even more sophisticated tools for identifying complex patterns of disease, leading to a more comprehensive understanding of soft tissue disorders.

Predictive analytics

Beyond direct diagnosis, AI's capabilities extend into predictive analytics, where large datasets of patient histories and outcomes are analyzed to identify trends and predict the likelihood of developing soft tissue diseases. By considering a multitude of factors, including genetic predispositions, environmental influences, and lifestyle choices, AI systems can provide valuable insights into individual risk profiles.[51]

For instance, patients with a family history of certain soft tissue cancers may benefit from predictive modeling that assesses their risk based on genetic markers. AI can analyze genomic data alongside clinical histories to identify at-risk individuals who may require more frequent monitoring or preventive interventions. This proactive approach can lead to earlier detection of diseases, which is often crucial in soft tissue cancers, where prognosis is significantly better when caught in the early stages.[52]

Moreover, the ability to analyze vast amounts of data allows AI to detect patterns that might not be immediately apparent to clinicians. By correlating specific lifestyle factors—such as diet, exercise, and exposure to environmental toxins—with the incidence of soft tissue disorders, AI can help inform public health strategies and individual patient management plans. This holistic view of patient health can lead to more personalized care and improved outcomes.[53,54]

As a result, the integration of AI into the diagnosis of soft tissue disorders is revolutionizing the field of medicine. From enhancing the accuracy of medical imaging analysis to automating the recognition of pathological abnormalities and providing predictive insights, AI is proving to be an invaluable tool for healthcare professionals. As these technologies continue to advance, they hold the promise of transforming not only how soft tissue diseases are diagnosed but also how they are managed, ultimately leading to better patient care and improved health outcomes. Embracing these

innovations will be essential for healthcare providers as they strive to meet the challenges of an ever-evolving medical landscape.[55,56]

Treatment planning for soft tissue conditions

The realm of soft tissue treatment is rapidly evolving, thanks to advancements in technology and the integration of AI into clinical practice.[57–59] As healthcare continues to move toward a more personalized and data-driven model, understanding the nuances of treatment planning for soft tissues becomes crucial.[60–62] This section explores how AI is revolutionizing treatment planning in soft tissue cases, including personalized medicine, surgical planning and simulation, and the use of robotic surgery.

Personalized medicine

In the landscape of healthcare, the concept of personalized medicine has emerged as a beacon of hope, particularly for patients suffering from soft tissue conditions. Traditional treatment approaches often adopt a one-size-fits-all mentality, which can lead to variable outcomes and suboptimal responses. However, AI has the potential to change this paradigm dramatically.[63,64] By leveraging large datasets that encompass patient histories, genetic profiles, and previous treatment responses, AI can facilitate the development of customized treatment plans tailored to the individual characteristics of each patient.[65,66]

For instance, consider a patient diagnosed with a soft tissue sarcoma. An AI system can analyze genetic data to identify specific mutations or biomarkers associated with the tumor. By correlating these findings with treatment outcomes from other patients who share similar genetic profiles, the AI can suggest targeted therapies that have proven effective in analogous cases. This not only enhances the likelihood of treatment success but also minimizes the risk of adverse effects, as therapies can be chosen based on their compatibility with the patient's unique biological makeup.

Moreover, AI can continuously learn and adapt its recommendations as new data becomes available. By incorporating the latest research findings and patient outcomes into its algorithms, AI systems can refine their suggestions over time, ensuring that treatment plans remain up-to-date and relevant. This dynamic approach to personalized medicine not only empowers healthcare providers to make more informed decisions but also fosters a collaborative relationship between patients and their medical teams, as individuals feel more involved in their care.[67–69]

Surgical planning and simulation

The intricacies involved in surgical procedures for soft tissue reconstruction present unique challenges that require meticulous planning and execution. AI tools have emerged as invaluable assets in this domain, particularly in the realm of surgical planning and simulation.[70,71] By utilizing advanced imaging techniques, such as MRI and CT scans, AI can create detailed 3D models of the patient's anatomy.[72,73] These models serve as a virtual representation of the soft tissues, allowing surgeons to visualize the surgical site in unprecedented detail.[74,75]

Through the use of AI-driven simulations, surgeons can explore various surgical approaches before stepping into the operating room. By manipulating the 3D models, they can assess the potential impact of different techniques on the surrounding soft tissues and identify the most effective strategies for achieving optimal outcomes.[76,77] This preoperative planning not only enhances the surgeon's confidence but also significantly reduces the risk of complications during the actual procedure. Furthermore, AI can assist in predicting surgical outcomes based on historical data from similar cases. By analyzing a vast array of surgical interventions and their results, AI algorithms can estimate the likelihood of success for various techniques in the context of a specific patient's anatomy and condition.[78,79] This predictive capability enables surgeons to make informed decisions about which approach to take, thereby increasing the chances of a favorable outcome.

Additionally, AI-driven surgical planning tools can facilitate communication among surgical teams.[79,80] By providing standardized models and simulations, these tools help ensure that all team members are aligned in their understanding of the surgical plan. This collaborative approach not only enhances teamwork but also contributes to a more efficient surgical process, ultimately benefiting patient care.

Robotic surgery

As technology continues to advance, the integration of AI-powered robotic systems into soft tissue surgeries represents a significant leap forward in surgical precision and patient safety.[81,82] These robotic systems (illustrated in Fig. 2 from the Scopus database) are designed to assist surgeons by providing enhanced dexterity and control during intricate procedures. Unlike traditional surgical methods, robotic assistance allows for minimally invasive approaches, which can lead to reduced recovery times and less postoperative pain for patients.[83,84]

One of the key advantages of AI in robotic surgery is its ability to offer real-time feedback to the surgeon. As the procedure unfolds, the robotic system can analyze the surgical field, monitor the surgeon's movements, and provide guidance to optimize technique.[85,86] For example, if the robot detects that a surgical instrument is approaching a critical anatomical structure, it can alert the surgeon, allowing for timely adjustments.[87] This level of assistance is particularly beneficial in soft tissue surgeries, where precision is paramount due to the delicate nature of the tissues involved.[88]

Moreover, the use of AI in robotic surgery enhances the surgeon's ability to navigate complex anatomical landscapes. In procedures involving soft tissues, such as tumor resections or reconstructive surgeries, the risk of damaging surrounding structures is high. AI-powered robotics can assist in mapping out the surgical field, identifying key landmarks, and ensuring that the surgeon maintains a safe distance from vital structures.[89] This not only minimizes the risk of complications but also improves overall surgical outcomes.

In addition to enhancing precision and safety, robotic systems equipped with AI can streamline surgical workflows. By automating certain aspects of the procedure, such as suturing or tissue manipulation, these systems free up the surgeon to focus on critical decision-making and complex maneuvers. This integration of AI and robotics ultimately leads to more efficient surgeries, allowing for a greater number of procedures to be performed while maintaining high standards of care.[90]

As a result, the integration of AI into treatment planning for soft tissue conditions is transforming the landscape of healthcare. Through personalized medicine, surgical planning and simulation, and the implementation of robotic surgery, AI is enhancing the precision, effectiveness, and safety of soft tissue interventions. As technology continues to evolve, the potential for AI to further improve patient outcomes in this domain remains limitless, ushering in a new era of tailored and effective healthcare solutions. By embracing these advancements, healthcare providers can better meet the unique needs of patients, ultimately leading to improved quality of life and enhanced recovery experiences.



Fig. 2. Visual flowchart representations of the primary functions performed by surgical robots through their various applications in the field.

Monitoring and rehabilitation of soft tissues

The journey to recovery from soft tissue injuries, such as strains, sprains, or post-surgical rehabilitation, requires meticulous monitoring and a tailored approach to rehabilitation. In recent years, advancements in technology, particularly through the integration of AI and wearable technology, have opened new avenues for enhancing patient care in this domain. This section delves into various innovative strategies that can significantly improve the monitoring and rehabilitation processes for patients suffering from soft tissue injuries.

Wearable technology in soft tissue recovery

Wearable technology has emerged as a game-changer in the realm of soft tissue rehabilitation. These AI-driven devices are designed to monitor a patient's recovery journey in real time, providing invaluable insights into their progress. By leveraging sensors and advanced algorithms, wearable devices can track various metrics such as movement patterns, range of motion, and even muscle activity.[91]

For instance, devices like smart braces or motion sensors can help assess how well a patient is adhering to their prescribed rehabilitation exercises. By collecting data on the quality and quantity of movement, healthcare professionals can receive immediate feedback on a patient's performance. This information can be instrumental in detecting any deviations from expected recovery trajectories, enabling practitioners to make timely adjustments to rehabilitation protocols.[92]

Moreover, wearables can facilitate patient engagement by allowing individuals to visualize their progress over time. Many devices come equipped with user-friendly interfaces that can display real-time data on metrics such as step count, joint angles, or even pain levels. This not only motivates patients to stay active but also fosters a sense of ownership over their rehabilitation process.[93] Ultimately, the integration of wearable technology into rehabilitation programs can lead to more personalized care, better adherence to exercise regimens, and improved overall outcomes for patients recovering from soft tissue injuries.[94]

Telemedicine and AI in soft tissue health

Telemedicine has revolutionized how healthcare is delivered, making it easier for patients to access care without the need for in-person visits. This has proven especially beneficial for individuals with soft tissue injuries who may require ongoing management and follow-up care. The integration of AI into telehealth applications can significantly enhance this experience by providing tailored support for patients navigating their recovery.[95,96]

AI algorithms can analyze a wealth of data, including patient-reported symptoms, activity levels, and even historical data from electronic health records. By utilizing this information, AI can generate actionable recommendations for follow-up care. For example, if a patient reports an increase in pain or discomfort during certain activities, AI can help identify patterns and suggest modifications to their rehabilitation program or recommend alternative therapies to alleviate symptoms.[97]

Additionally, AI-powered telehealth platforms can streamline communication between patients and healthcare providers. By offering virtual consultations, practitioners can monitor a patient's progress and make real-time adjustments to treatment plans based on the latest data. This approach not only ensures that patients receive prompt attention when issues arise but also fosters a collaborative relationship between patients and providers. As a result, telemedicine combined with AI can lead to more efficient management of soft tissue conditions, particularly for chronic issues that require ongoing assessment and adjustments.[95,98]

Predictive monitoring for soft tissue complications

The potential of AI extends beyond real-time monitoring and rehabilitation adjustments; it can also play a crucial role in predic-

tive monitoring. This involves analyzing a patient's data to identify those at risk of complications stemming from soft tissue injuries or surgical interventions. By leveraging machine learning algorithms, healthcare providers can proactively address potential issues before they escalate into more serious concerns.[51,78]

For example, predictive monitoring can be particularly useful in identifying patients who may experience delayed healing or other complications. By examining data from electronic health records, including factors such as age, medical history, and the nature of the injury, AI can flag patients who may require more intensive monitoring or intervention. This proactive approach enables healthcare providers to allocate resources more effectively, ensuring that those at higher risk receive the attention they need.[51,79]

Furthermore, predictive analytics can enhance clinical decision-making by providing insights into the most effective rehabilitation strategies for individual patients. By analyzing data from previous cases, AI can help identify which rehabilitation protocols work best for specific types of soft tissue injuries. This allows healthcare providers to tailor their approach based on evidence, ultimately leading to improved outcomes for patients.[55]

Incorporating predictive monitoring into soft tissue rehabilitation not only enhances patient safety but also has the potential to reduce healthcare costs. By catching complications early and intervening promptly, healthcare providers can minimize the likelihood of extended recovery times or the need for more invasive treatments.[79]

As these technologies continue to evolve, they hold the promise of transforming the rehabilitation experience for patients with soft tissue injuries, fostering a more efficient, effective, and patient-centered approach to care. The future of soft tissue recovery looks bright, with the potential for these innovations to enhance the quality of life for countless individuals navigating their healing journey.

Research and development in soft tissue therapies

The field of soft tissue research and development has witnessed significant advancements in recent years, particularly with the integration of AI technologies. The potential of AI to transform the landscape of drug discovery, clinical trials, and biomechanical analysis is profound and offers promise for improving therapeutic outcomes for patients suffering from a variety of soft tissue diseases. This section delves into these three key areas, highlighting how AI is being leveraged to enhance the understanding and treatment of soft tissue conditions.

Drug discovery for soft tissue diseases

The process of discovering and developing new drugs is inherently complex, often requiring years of research and substantial financial investment. Traditionally, this process has relied heavily on empirical methods, which can be time-consuming and inefficient. However, the advent of AI has ushered in a new era in drug discovery, particularly for soft tissue diseases such as fibromatosis and soft tissue sarcomas.[16]

AI technologies, particularly machine learning algorithms, are now being employed to analyze vast datasets of chemical compounds. These algorithms can sift through hundreds of thousands of potential drug candidates, evaluating their chemical structures and biological properties to predict their efficacy against specific soft tissue conditions. By leveraging historical data, AI can identify patterns and correlations that might be missed by human researchers, thereby accelerating the identification of promising drug candidates.[55,97]

For instance, in the context of soft tissue sarcomas, AI can help researchers identify compounds that not only inhibit tumor growth but also target the specific genetic mutations associated with these cancers. This targeted approach is critical, as it allows for the development of personalized therapies that are tailored to the individual genetic profiles of patients, enhancing the likelihood of successful treatment outcomes.[55]

Moreover, AI can assist in predicting adverse drug reactions and interactions, which is particularly important in the treatment of soft tissue diseases where patients may be undergoing multiple therapies. By simulating how different compounds interact within biological systems, AI can help researchers make informed decisions about which drug candidates to advance to clinical trials.[55,96,97]

Optimizing clinical trials for soft tissue conditions

The design and execution of clinical trials are essential for evaluating the safety and effectiveness of new therapies. However, these trials often face numerous challenges, including the identification of suitable patient populations, the management of diverse data sets, and the minimization of bias.[99–101] AI has emerged as a powerful tool to address these challenges, particularly in the context of soft tissue conditions.

One of the primary advantages of using AI in clinical trials is its ability to analyze vast amounts of patient data quickly and accurately. By employing advanced algorithms, researchers can identify specific patient demographics that are more likely to benefit from particular therapies for soft tissue diseases. This targeted approach not only enhances the likelihood of positive trial outcomes but also ensures that the findings are more generalizable to the broader patient population.

Additionally, AI can assist in predicting trial outcomes based on historical data and current patient characteristics. By modeling potential results, researchers can refine their study designs and make data-driven adjustments that increase the likelihood of success. This predictive capability is particularly valuable in soft tissue conditions, where the variability of patient responses can complicate trial results.

Another critical aspect of clinical trials is the need to minimize bias in data collection. AI can help standardize data collection methods and ensure that all relevant variables are accounted for, thereby enhancing the validity of trial results. By automating aspects of data management, AI also reduces the risk of human error, leading to more reliable findings.

Furthermore, AI can facilitate patient recruitment by identifying individuals who meet specific criteria for participation in trials. This can be especially beneficial for rare soft tissue conditions, where finding enough eligible patients can be a significant barrier to conducting research. By streamlining the recruitment process, AI can help accelerate the timeline for clinical trials and bring new therapies to market more quickly. As a result, the application of AI in optimizing clinical trials for soft tissue conditions represents a paradigm shift in how research is conducted. By harnessing the power of data analysis and predictive modeling, researchers can enhance the efficiency and effectiveness of clinical trials, ultimately leading to the development of new and improved therapies for patients with soft tissue diseases.

Advancing biomechanical analysis of soft tissues

Understanding the mechanical properties of soft tissues is crucial for developing effective treatment strategies and medical devices. The field of biomechanics focuses on how tissues respond to forc-

es and loads, which has significant implications for both injury prevention and rehabilitation. AI is playing an increasingly vital role in advancing biomechanical analysis, particularly in relation to soft tissue injuries.

AI algorithms can analyze data from various sources, including imaging studies, biomechanical measurements, and patient-reported outcomes. This comprehensive analysis helps researchers gain insights into how different soft tissues react to physical stressors, which can inform treatment decisions and the design of therapeutic interventions. For example, understanding the mechanical behavior of soft tissues can aid in the development of tailored rehabilitation programs that optimize recovery after injury.[1,55]

Moreover, AI can assist in the design of medical devices, such as prosthetics and orthopedic implants, by modeling how these devices interact with soft tissues under different conditions. By simulating various scenarios, researchers can better understand how to improve the fit and functionality of these devices, ultimately enhancing patient outcomes. Additionally, AI-driven biomechanical research can contribute to the identification of risk factors for soft tissue injuries. By analyzing patterns in movement and stress distribution, AI can help pinpoint individuals who are more susceptible to injuries, allowing for preemptive measures to be taken.[1,43]

Briefly, the integration of AI into biomechanical analysis has the potential to revolutionize our understanding of soft tissues. By providing deeper insights into their mechanical properties and responses, AI can guide the development of innovative treatment strategies and medical devices, ultimately improving patient care and outcomes for those affected by soft tissue injuries and diseases.[1,55,97]

Challenges of using AI in soft tissues

This section presents the main challenges related to the use of AI in soft tissues. AI holds immense potential to revolutionize the diagnosis, treatment, and management of soft tissue disorders. However, its implementation is confronted with critical challenges that must be addressed to fully realize its capabilities.

Data security and patient privacy are paramount concerns. AI systems depend on vast quantities of sensitive health data, including medical images, genetic information, electronic health records, and personal identifiers.[97,102] The storage, transmission, and processing of this data inherently carry significant risks of breaches, unauthorized access, and misuse. Despite the necessity of robust cybersecurity measures, the rapidly evolving landscape of cyber threats often outstrips current defenses, leaving patient information vulnerable. Compliance with data protection regulations such as GDPR and HIPAA further complicates data sharing and collaboration, often hindering the development and deployment of AI solutions.[55,102]

Algorithmic biases pose a substantial obstacle to AI effectiveness. Many models are trained on datasets that lack sufficient diversity, frequently originating from specific populations or geographic areas. This leads to biased predictions and diminished accuracy when applied across different demographic groups, potentially worsening health disparities. For example, AI trained predominantly on data from certain ethnicities or age groups may perform poorly in underrepresented populations, undermining trust in AI-driven healthcare.[102,103]

The quality and completeness of training data further limit AI performance. Medical datasets often contain errors, inconsistencies, or missing information, which can propagate inaccuracies in AI outputs. Additionally, the complexity and opaqueness of many AI algorithms, particularly deep learning models, restrict interpretability. This "black box" nature hampers clinicians' ability to understand and trust AI recommendations, complicating clinical decision-making and accountability.[97,102]

Integrating AI into clinical workflows requires significant infrastructural investment. Adoption involves upgrading hardware, implementing sophisticated software, and providing extensive staff training. Resistance from clinicians skeptical of automation or concerned about job security can impede progress. Moreover, the regulatory environment remains in flux; approval processes for AI tools are often slow, delaying widespread clinical deployment and limiting access to cutting-edge technologies.[103]

Limited availability of high-quality, annotated datasets remains a major barrier. Rare soft tissue conditions lack sufficient data for robust model training, and cross-institutional data sharing is hindered by legal, proprietary, and logistical obstacles. Consequently, AI models trained in one setting or population may not perform reliably elsewhere, necessitating costly validation and calibration efforts.[55] While these technical and infrastructural challenges are significant, the most pressing issues lie in establishing clear accountability and ensuring transparency. When AI systems influence clinical decisions, determining responsibility for errors becomes complex. Patients must be informed about the role AI plays in their care, requiring transparent communication and consent processes. Over-reliance on AI at the expense of clinical judgment can compromise patient safety, underscoring the importance of balanced integration that augments rather than replaces human expertise.[97,102,104]

Addressing these challenges demands concerted collaboration among technologists, clinicians, regulators, and stakeholders. Developing secure, unbiased, and transparent AI systems will be instrumental in advancing soft tissue disorder management, ultimately enhancing patient outcomes and healthcare quality on a broad scale.[103,104]

Ethical considerations for AI in soft tissues

The previous section highlighted the challenges associated with implementing AI in soft tissue applications. Building on that foundation, this section addresses the critical ethical considerations that must be rigorously managed to ensure responsible and equitable healthcare. The deployment of AI in diagnosing, treating, and managing soft tissue disorders raises profound ethical questions that demand decisive action. Primarily, safeguarding patient autonomy and informed consent is paramount. As AI becomes increasingly embedded in clinical decision-making, patients must be fully informed about how their data are utilized, the extent of AI's influence on their diagnosis and treatment, and the implications of automated decisions. Transparency is non-negotiable; patients have an absolute right to understand the role AI plays in their care, including its limitations and inherent uncertainties. Upholding transparency builds trust and empowers patients to make informed choices about their healthcare.[105,106]

Equally vital is our obligation to the principle of beneficence, ensuring AI applications deliver genuine improvements in patient outcomes. While AI exhibits high accuracy in detecting soft tissue abnormalities, over-reliance on algorithms that may overlook nuanced clinical contexts poses risks. Ethical deployment necessitates rigorous validation, continuous performance monitoring, and addressing potential biases that could lead to misdiagnoses or suboptimal treatments, especially among vulnerable populations. Healthcare providers must critically evaluate AI recommendations,

maintaining their clinical judgment to prevent automation from undermining the essential human element of patient care.[107,108]

Justice and equity represent fundamental concerns. AI systems trained on limited or non-representative datasets threaten to marginalize underserved populations, thereby deepening existing disparities in healthcare access and quality. Ethical AI development must prioritize inclusivity, ensuring datasets reflect diverse demographic and clinical profiles. Such efforts promote fairness and prevent the reinforcement of social inequalities. Moreover, equitable access to AI-driven healthcare must be actively pursued, particularly in resource-constrained settings, to avoid creating a technological divide that benefits only privileged groups.

Data privacy and confidentiality are at the core of ethical practice. AI systems rely heavily on extensive personal health data, which raises serious concerns about data security, sharing, and protection. The risk of breaches or misuse carries severe personal and social consequences. Developers and healthcare institutions bear the responsibility to implement stringent security protocols, comply with legal standards, and secure explicit patient consent for data collection and use. Patients must retain control over their information, with clear options to opt out or restrict data sharing, thereby respecting their rights and dignity.[107,109]

The opacity of many AI algorithms, often termed "black boxes", poses significant ethical challenges related to accountability and explainability. When AI influences critical healthcare decisions, clinicians and patients need clarity on how conclusions are derived. Lack of transparency can erode trust and complicate accountability, especially in cases of errors or adverse outcomes. Ethical AI development must prioritize explainable models and comprehensive documentation, enabling clinicians to interpret AI outputs and communicate them effectively to patients. Another pressing ethical issue concerns the potential impact of AI on employment and professional roles within healthcare. While AI can augment clinical capabilities, there is legitimate concern about automation displacing human expertise and reducing employment opportunities. Responsible implementation requires a balanced approach that respects healthcare professionals' judgment and well-being, ensuring AI serves as a supportive tool rather than a replacement. Finally, the development and deployment of AI must adhere to principles of responsible innovation, focusing on fairness, safety, and respect for human rights. Robust regulatory frameworks should oversee AI applications through rigorous testing, validation, and ongoing surveillance. Ethical oversight must be multidisciplinary, involving ethicists, patient advocates, and policymakers to align AI advances with societal values and uphold individual rights.

As a result, integrating AI into soft tissue disorder management offers tremendous promise, but it also imposes significant ethical responsibilities. Protecting patient autonomy, ensuring fairness, maintaining transparency, safeguarding data privacy, and fostering responsible innovation are essential to harness AI's benefits without compromising core ethical principles. Proactive engagement with these considerations will foster trust, promote equity, and uphold the integrity of healthcare in this rapidly evolving digital landscape.

Future directions

As we look to the future, the integration of AI in soft tissue diagnosis and management is poised for significant advancements. Key directions include enhancing the interpretability of AI algorithms to foster clinician trust and facilitate broader adoption. Research should prioritize developing frameworks that address data privacy and security while ensuring equitable access to AI tools across diverse populations.

Interdisciplinary collaboration among clinicians, data scientists, and ethicists will be essential in establishing guidelines for responsible AI deployment. Expanding AI applications in real-time monitoring and personalized rehabilitation can further improve patient outcomes. Continuous education and training for healthcare professionals on AI applications will be vital to maximize its benefits. Moreover, addressing challenges such as algorithmic bias and the "black box" nature of AI models will be crucial for ethical integration. By fostering a culture of innovation and responsibility, AI can transform soft tissue medicine, paving the way for more precise, efficient, and compassionate patient care. Ultimately, proactive adaptation by stakeholders will be essential to harness AI's full potential while upholding ethical standards.

Conclusions

This review highlights the transformative impact of AI on soft tissue diagnosis and management. Key findings indicate that AI technologies, including advanced imaging analysis, predictive analytics, and robotic surgery, significantly enhance the accuracy and efficiency of care. AI improves medical imaging by enabling rapid detection of abnormalities, often outperforming traditional methods. In pathology, AI algorithms automate slide analysis, expediting diagnosis and facilitating timely treatment for cancers and inflammatory conditions.

AI's predictive capabilities support early risk stratification and personalized treatment planning by analyzing genetic, clinical, and lifestyle data. In surgical settings, AI enhances preoperative planning and robotic assistance, promoting minimally invasive procedures and improving patient outcomes. Additionally, AI-driven monitoring through wearable devices and telemedicine fosters patient engagement and optimizes recovery.

Despite these advancements, challenges such as data privacy, algorithmic bias, and the need for interpretability remain. Ethical considerations, including patient autonomy and equitable access, are crucial for responsible AI integration. Overall, AI presents unprecedented opportunities for personalized healthcare, but addressing technical and ethical challenges is essential for its successful implementation in soft tissue medicine. With collaborative efforts, AI can significantly advance patient care while upholding ethical standards.

Acknowledgments

The author would like to thank the funders for their support.

Funding

This work was supported by Damascus University (https://damascusuniversity.edu.sy), International University for Science and Technology (https://iust.edu.sy/), Al-Andalus University (https://au.edu.sy), and Cordoba Private University (https://cpu.edu.sy/).

Conflict of interest

The author has no conflicts of interest.

Author contributions

MA is the sole author of the manuscript.

References

[1] Holzapfel GA. Biomechanics of soft tissue. In: Lemaitre J (ed). Handbook of materials behavior models. Burlington: Academic Press; 2001:1057–1071. doi:10.1016/B978-012443341-0/50107-1.

[2] Thoma DS, Gil A, Hämmerle CHF, Jung RE. Management and prevention of soft tissue complications in implant dentistry. Periodontol 2000 2022;88(1):116–129. doi:10.1111/prd.12415, PMID:35103320.

[3] Mazzoni E, Iaquinta MR, Lanzillotti C, Mazziotta C, Maritati M, Montesi M, *et al*. Bioactive Materials for Soft Tissue Repair. Front Bioeng Biotechnol 2021;9:613787. doi:10.3389/fbioe.2021.613787, PMID: 33681157.

[4] Choi JH, Ro JY. The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv Anat Pathol 2021;28(1):44–58. doi:10.1097/PAP.0000000000000284, PMID:32960834.

[5] Osailan A, Jamaan A, Talha K, Alhndi M. Instrument assisted soft tissue mobilization (IASTM) versus stretching: A comparison in effectiveness on hip active range of motion, muscle torque and power in people with hamstring tightness. J Bodyw Mov Ther 2021;27:200–206. doi:10.1016/j.jbmt.2021.03.001, PMID:34391234.

[6] Guirguis M, Sharan G, Wang J, Chhabra A. Diffusion-weighted MR imaging of musculoskeletal tissues: incremental role over conventional MR imaging in bone, soft tissue, and nerve lesions. BJR Open 2022;4(1):20210077. doi:10.1259/bjro.20210077, PMID:36452057.

[7] Al-Raeei M. Harnessing nanoscale innovations for enhanced healing of diabetic foot ulcers. Endocr Metab Sci 2025;17:100210. doi:10.1016/j.endmts.2024.100210.

[8] Di Matteo A, Smerilli G, Cipolletta E, Salaffi F, De Angelis R, Di Carlo M, *et al*. Imaging of Joint and Soft Tissue Involvement in Systemic Lupus Erythematosus. Curr Rheumatol Rep 2021;23(9):73. doi:10.1007/s11926-021-01040-8, PMID:34269905.

[9] Moulin B, Messiou C, Crombe A, Kind M, Hohenberger P, Rutkowski P, *et al*. Diagnosis strategy of adipocytic soft-tissue tumors in adults: a consensus from European experts. Eur J Surg Oncol 2022;48(3):518–525. doi:10.1016/j.ejso.2021.10.009, PMID:34688512.

[10] Sack I. Magnetic resonance elastography from fundamental soft-tissue mechanics to diagnostic imaging. Nat Rev Phys 2023;5(1):25–42. doi:10.1038/s42254-022-00543-2.

[11] Al-Raeei M. Trends in the applications of terahertz radiation in oral oncology treatments. Oral Oncol Rep 2024;10:100402. doi:10.1016/j.oor.2024.100402.

[12] Kwee RM, Kwee TC. Diagnostic performance of MRI and CT in diagnosing necrotizing soft tissue infection: a systematic review. Skeletal Radiol 2022;51(4):727–736. doi:10.1007/s00256-021-03875-9, PMID:34302500.

[13] Scalas G, Parmeggiani A, Martella C, Tuzzato G, Bianchi G, Facchini G, *et al*. Magnetic resonance imaging of soft tissue sarcoma: features related to prognosis. Eur J Orthop Surg Traumatol 2021;31(8):1567–1575. doi:10.1007/s00590-021-03003-2, PMID:34052920.

[14] Almășan O, Kui A, Duncea I, Manea A, Buduru S. Temporomandibular Joint Disk Displacements in Class II Malocclusion and Cervical Spine Alterations: Systematic Review and Report of a Hypodivergent Case with MRI Bone and Soft Tissue Changes. Life (Basel) 2022;12(6):908. doi:10.3390/life12060908, PMID:35743939.

[15] Benz MR, Crompton JG, Harder D. PET/CT Variants and Pitfalls in Bone and Soft Tissue Sarcoma. Semin Nucl Med 2021;51(6):584–592. doi:10.1053/j.semnuclmed.2021.06.009, PMID:34238508.

[16] Gu B, Liu X, Wang S, Xu X, Liu X, Hu S, *et al*. Head-to-head evaluation of [(18)F]FDG and [(68) Ga]Ga-DOTA-FAPI-04 PET/CT in recurrent soft tissue sarcoma. Eur J Nucl Med Mol Imaging 2022;49(8):2889–2901. doi:10.1007/s00259-022-05700-4, PMID:35113192.

[17] Jacobson JA, Middleton WD, Allison SJ, Dahiya N, Lee KS, Levine BD, *et al*. Ultrasonography of Superficial Soft-Tissue Masses: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology 2022;304(1):18–30. doi:10.1148/radiol.211101, PMID:35412355.

[18] Qin H, Du L, Luo Z, He Z, Wang Q, Chen S, *et al*. The therapeutic effects of low-intensity pulsed ultrasound in musculoskeletal soft tissue injuries: Focusing on the molecular mechanism. Front Bioeng Biotechnol 2022;10:1080430. doi:10.3389/fbioe.2022.1080430, PMID: 36588943.

[19] Donmazov S, Saruhan EN, Pekkan K, Piskin S. Review of Machine Learning Techniques in Soft Tissue Biomechanics and Biomaterials. Cardiovasc Eng Technol 2024;15(5):522–549. doi:10.1007/s13239-024-00737-y, PMID:38956008.

[20] Roberts DA, Yaida S, Hanin B. The principles of deep learning theory. Vol. 46. Cambridge, MA: Cambridge University Press 2022;doi:10.1017/9781009023405.

[21] Sharma S, Subbarao N, Jha SK, McKenna S. Revolutionizing healthcare. In: Jain S, Srivastava V, Singal G, Mosbah M (eds). Transforming Healthcare: Mode, Technologies, and Implementation, 1st ed. Boca Raton: CRC Press; 2025. doi:10.1201/9781003634089-11.

[22] Matsuo Y, LeCun Y, Sahani M, Precup D, Silver D, Sugiyama M, *et al*. Deep learning, reinforcement learning, and world models. Neural Netw 2022;152:267–275. doi:10.1016/j.neunet.2022.03.037, PMID:35569196.

[23] Tekouabou SC, Hartini S, Rustam Z, Silkan H, Agoujil S. Improvement in automated diagnosis of soft tissues tumors using machine learning. Big Data Min Anal 2021;4(1):33–46. doi:10.26599/BDMA.2020.9020023.

[24] Ricci V, Ricci C, Cocco G, Donati D, Farì G, Mezian K, *et al*. From histology to sonography in skin and superficial tissue disorders: EUROMUSCULUS/USPRM* approach. Pathol Res Pract 2022;237:154003. doi:10.1016/j.prp.2022.154003, PMID:35843035.

[25] Hill LR, Duis J, Kulungowski AM, Annam A, Siegele B, Nakano TA. A challenging diagnosis: PTEN hamartoma tumor syndrome presenting as isolated soft-tissue vascular anomalies. J Vasc Anom 2021;2(2):e011. doi:10.1097/JOVA.0000000000000011.

[26] Giuliani A, Furlani M, Riberti N. Soft tissues and force fields: advanced 3D synchrotron-based imaging for diagnostics and regenerative medicine. In: Duma VF, Rolland-Thompson JP, Podoleanu AGH, Guina M, Sinescu C (eds). Advances in 3OM: Opto-Mechatronics, Opto-Mechanics, and Optical Metrology; 2023 Dec 11-14; Timisoara, Romania. Vol 13187. Bellingham, WA: SPIE; 2024:1318703. doi:10.1117/12.3016226.

[27] Hussain S, Mubeen I, Ullah N, Shah SSUD, Khan BA, Zahoor M, *et al*. Modern Diagnostic Imaging Technique Applications and Risk Factors in the Medical Field: A Review. Biomed Res Int 2022;2022:5164970. doi:10.1155/2022/5164970, PMID:35707373.

[28] Pinto-Coelho L. How Artificial Intelligence Is Shaping Medical Imaging Technology: A Survey of Innovations and Applications. Bioengineering (Basel) 2023;10(12):1435. doi:10.3390/bioengineering10121435, PMID:38136026.

[29] Avanzo M, Porzio M, Lorenzon L, Milan L, Sghedoni R, Russo G, *et al*. Artificial intelligence applications in medical imaging: A review of the medical physics research in Italy. Phys Med 2021;83:221–241. doi:10.1016/j.ejmp.2021.04.010, PMID:33951590.

[30] Wang S, Cao G, Wang Y, Liao S, Wang Q, Shi J, *et al*. Review and Prospect: Artificial Intelligence in Advanced Medical Imaging. Front Radiol 2021;1:781868. doi:10.3389/fradi.2021.781868, PMID:37492170.

[31] Sabeghi P, Kinkar KK, Castaneda GDR, Eibschutz LS, Fields BKK, Varghese BA, *et al*. Artificial intelligence and machine learning applications for the imaging of bone and soft tissue tumors. Front Radiol 2024;4:1332535. doi:10.3389/fradi.2024.1332535, PMID:39301168.

[32] Zheng Q, Yang L, Zeng B, Li J, Guo K, Liang Y, *et al*. Artificial intelligence performance in detecting tumor metastasis from medical radiology imaging: A systematic review and meta-analysis. EClinicalMedicine 2021;31:100669. doi:10.1016/j.eclinm.2020.100669, PMID:33392486.

[33] Olveres J, González G, Torres F, Moreno-Tagle JC, Carbajal-Degante E, Valencia-Rodríguez A, *et al*. What is new in computer vision and artificial intelligence in medical image analysis applications. Quant Imaging Med Surg 2021;11(8):3830–3853. doi:10.21037/qims-20-1151, PMID:34341753.

[34] Barragán-Montero A, Javaid U, Valdés G, Nguyen D, Desbordes P, Macq B, *et al*. Artificial intelligence and machine learning for medical imaging: A technology review. Phys Med 2021;83:242–256. doi:10.1016/j.ejmp.2021.04.016, PMID:33979715.

[35] Khalifa M, Albadawy M. AI in diagnostic imaging: Revolutionising accuracy and efficiency. Comput Methods Programs Biomed Update 2024;5:100146. doi:10.1016/j.cmpbup.2024.100146.

[36] Shah SM, Khan RA, Arif S, Sajid U. Artificial intelligence for breast cancer analysis: Trends & directions. Comput Biol Med 2022;142:105221.

doi:10.1016/j.compbiomed.2022.105221, PMID:35016100.
[37] Crombé A, Spinnato P, Italiano A, Brisse HJ, Feydy A, Fadli D, *et al*. Radiomics and artificial intelligence for soft-tissue sarcomas: Current status and perspectives. Diagn Interv Imaging 2023;104(12):567–583. doi:10.1016/j.diii.2023.09.005, PMID:37802753.
[38] Soomro TA, Zheng L, Afifi AJ, Ali A, Yin M, Gao J. Artificial intelligence (AI) for medical imaging to combat coronavirus disease (COVID-19): a detailed review with direction for future research. Artif Intell Rev 2022;55(2):1409–1439. doi:10.1007/s10462-021-09985-z, PMID:33875900.
[39] Ren S, Qian LC, Cao YY, Daniels MJ, Song LN, Tian Y, *et al*. Computed tomography-based radiomics diagnostic approach for differential diagnosis between early- and late-stage pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2024;16(4):1256–1267. doi:10.4251/wjgo.v16.i4.1256, PMID:38660647.
[40] Ren S, Song L, Daniels MJ, Tian Y, Wang Z. ChatGPT in Radiology: Insights into Current Advantages and Limitations of Artificial Intelligence in Radiology Reporting. Explor Res Hypothesis Med 2025;10(1):75–76. doi:10.14218/ERHM.2024.00016.
[41] Försch S, Klauschen F, Hufnagl P, Roth W. Artificial Intelligence in Pathology. Dtsch Arztebl Int 2021;118(12):194–204. doi:10.3238/arztebl.m2021.0011, PMID:34024323.
[42] Song AH, Jaume G, Williamson DF, Lu MY, Vaidya A, Miller TR, Mahmood F. Artificial intelligence for digital and computational pathology. Nat Rev Bioeng 2023;1(12):930–949. doi:10.1038/s44222-023-00096-8.
[43] Lancellotti C, Cancian P, Savevski V, Kotha SRR, Fraggetta F, Graziano P, *et al*. Artificial Intelligence & Tissue Biomarkers: Advantages, Risks and Perspectives for Pathology. Cells 2021;10(4):787. doi:10.3390/cells10040787, PMID:33918173.
[44] Rodriguez JPM, Rodriguez R, Silva VWK, Kitamura FC, Corradi GCA, de Marchi ACB, *et al*. Artificial intelligence as a tool for diagnosis in digital pathology whole slide images: A systematic review. J Pathol Inform 2022;13:100138. doi:10.1016/j.jpi.2022.100138, PMID:36268059.
[45] Zuraw A, Aeffner F. Whole-slide imaging, tissue image analysis, and artificial intelligence in veterinary pathology: An updated introduction and review. Vet Pathol 2022;59(1):6–25. doi:10.1177/03009858211040484, PMID:34521285.
[46] Durkee MS, Abraham R, Clark MR, Giger ML. Artificial Intelligence and Cellular Segmentation in Tissue Microscopy Images. Am J Pathol 2021;191(10):1693–1701. doi:10.1016/j.ajpath.2021.05.022, PMID:34129842.
[47] Pantanowitz L, Wu U, Seigh L, LoPresti E, Yeh FC, Salgia P, *et al*. Artificial Intelligence-Based Screening for Mycobacteria in Whole-Slide Images of Tissue Samples. Am J Clin Pathol 2021;156(1):117–128. doi:10.1093/ajcp/aqaa215, PMID:33527136.
[48] Cui M, Zhang DY. Artificial intelligence and computational pathology. Lab Invest 2021;101(4):412–422. doi:10.1038/s41374-020-00514-0, PMID:33454724.
[49] Yousif M, van Diest PJ, Laurinavicius A, Rimm D, van der Laak J, Madabhushi A, *et al*. Artificial intelligence applied to breast pathology. Virchows Arch 2022;480(1):191–209. doi:10.1007/s00428-021-03213-3, PMID:34791536.
[50] Viswanathan VS, Toro P, Corredor G, Mukhopadhyay S, Madabhushi A. The state of the art for artificial intelligence in lung digital pathology. J Pathol 2022;257(4):413–429. doi:10.1002/path.5966, PMID:35579955.
[51] Cherfaoui M, Chouiter F. Artificial intelligence application for diabetes prediction [Dissertation]. Bordj Bou Arréridj: Faculté des sciences et de la technologie; 2025.
[52] Peeken JC, Goldberg T, Knie C, Komboz B, Bernhofer M, Pasa F, *et al*. Treatment-related features improve machine learning prediction of prognosis in soft tissue sarcoma patients. Strahlenther Onkol 2018;194(9):824–834. doi:10.1007/s00066-018-1294-2, PMID:29557486.
[53] Holzinger A, Keiblinger K, Holub P, Zatloukal K, Müller H. AI for life: Trends in artificial intelligence for biotechnology. N Biotechnol 2023;74:16–24. doi:10.1016/j.nbt.2023.02.001, PMID:36754147.
[54] Yuvaraj A, Yadalam PK, Karthickraj SM, Manogaran S, Ayyachamy S. Predictive analytics in dentistry: AI applications in frenectomy and soft tissue management. 2025 Eleventh International Conference on Bio Signals, Images, and Instrumentation (ICBSII). 2025:1–5. doi:10.1109/ICBSII65145.2025.11014020.
[55] Al-Raeei M. The role of artificial intelligence in enhancing breast disease management: early detection and prognostic innovations. Arch Med Health Sci 2025. doi:10.4103/amhs.amhs_351_24.
[56] Halvachizadeh S, Klingebiel FKL, Pfeifer R, Gosteli M, Schuerle S, Cinelli P, *et al*. The local soft tissue status and the prediction of local complications following fractures of the ankle region. Injury 2022;53(6):1789–1795. doi:10.1016/j.injury.2022.03.037, PMID:35382943.
[57] Salazar D, Rossouw PE, Javed F, Michelogiannakis D. Artificial intelligence for treatment planning and soft tissue outcome prediction of orthognathic treatment: A systematic review. J Orthod 2024;51(2):107–119. doi:10.1177/14653125231203743, PMID:37772513.
[58] Farhud DD, Zokaei S. Ethical Issues of Artificial Intelligence in Medicine and Healthcare. Iran J Public Health 2021;50(11):i–v. doi:10.18502/ijph.v50i11.7600, PMID:35223619.
[59] Thornton JM, Laskowski RA, Borkakoti N. AlphaFold heralds a data-driven revolution in biology and medicine. Nat Med 2021;27(10):1666–1669. doi:10.1038/s41591-021-01533-0, PMID:34642488.
[60] Sankar H, Alagarsamy R, Lal B, Rana SS, Roychoudhury A, Agrawal A, *et al*. Role of artificial intelligence in treatment planning and outcome prediction of jaw corrective surgeries by using 3-D imaging: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol 2025;139(3):299–310. doi:10.1016/j.oooo.2024.09.010, PMID:39701860.
[61] de Hond AAH, Leeuwenberg AM, Hooft L, Kant IMJ, Nijman SWJ, van Os HJA, *et al*. Guidelines and quality criteria for artificial intelligence-based prediction models in healthcare: a scoping review. NPJ Digit Med 2022;5(1):2. doi:10.1038/s41746-021-00549-7, PMID:35013569.
[62] Lee EE, Torous J, De Choudhury M, Depp CA, Graham SA, Kim HC, *et al*. Artificial Intelligence for Mental Health Care: Clinical Applications, Barriers, Facilitators, and Artificial Wisdom. Biol Psychiatry Cogn Neurosci Neuroimaging 2021;6(9):856–864. doi:10.1016/j.bpsc.2021.02.001, PMID:33571718.
[63] Rezayi S, R Niakan Kalhori S, Saeedi S. Effectiveness of Artificial Intelligence for Personalized Medicine in Neoplasms: A Systematic Review. Biomed Res Int 2022;2022:7842566. doi:10.1155/2022/7842566, PMID:35434134.
[64] Ahn JS, Shin S, Yang SA, Park EK, Kim KH, Cho SI, *et al*. Artificial Intelligence in Breast Cancer Diagnosis and Personalized Medicine. J Breast Cancer 2023;26(5):405–435. doi:10.4048/jbc.2023.26.e45, PMID:37926067.
[65] Vadapalli S, Abdelhalim H, Zeeshan S, Ahmed Z. Artificial intelligence and machine learning approaches using gene expression and variant data for personalized medicine. Brief Bioinform 2022;23(5):bbac191. doi:10.1093/bib/bbac191, PMID:35595537.
[66] Li LR, Du B, Liu HQ, Chen C. Artificial Intelligence for Personalized Medicine in Thyroid Cancer: Current Status and Future Perspectives. Front Oncol 2020;10:604051. doi:10.3389/fonc.2020.604051, PMID:33634025.
[67] Lin B, Wu S. Digital Transformation in Personalized Medicine with Artificial Intelligence and the Internet of Medical Things. OMICS 2022;26(2):77–81. doi:10.1089/omi.2021.0037, PMID:33887155.
[68] Alrefaei AF, Hawsawi YM, Almaleki D, Alafif T, Alzahrani FA, Bakhrebah MA. Genetic data sharing and artificial intelligence in the era of personalized medicine based on a cross-sectional analysis of the Saudi human genome program. Sci Rep 2022;12(1):1405. doi:10.1038/s41598-022-05296-7, PMID:35082362.
[69] Bonkhoff AK, Grefkes C. Precision medicine in stroke: towards personalized outcome predictions using artificial intelligence. Brain 2022;145(2):457–475. doi:10.1093/brain/awab439, PMID:34918041.
[70] Park JJ, Tiefenbach J, Demetriades AK. The role of artificial intelligence in surgical simulation. Front Med Technol 2022;4:1076755. doi:10.3389/fmedt.2022.1076755, PMID:36590155.
[71] Shujaat S, Riaz M, Jacobs R. Synergy between artificial intelligence and precision medicine for computer-assisted oral and maxillofacial surgical planning. Clin Oral Investig 2023;27(3):897–906.

doi:10.1007/s00784-022-04706-4, PMID:36323803.
[72] Costello DM, Huntington I, Burke G, Farrugia B, O'Connor AJ, Costello AJ, *et al*. A review of simulation training and new 3D computer-generated synthetic organs for robotic surgery education. J Robot Surg 2022;16(4):749–763. doi:10.1007/s11701-021-01302-8, PMID:34480323.
[73] Johnson GW, Chanbour H, Ali MA, Chen J, Metcalf T, Doss D, *et al*. Artificial Intelligence to Preoperatively Predict Proximal Junction Kyphosis Following Adult Spinal Deformity Surgery: Soft Tissue Imaging May Be Necessary for Accurate Models. Spine (Phila Pa 1976) 2023;48(23):1688–1695. doi:10.1097/BRS.0000000000004816, PMID:37644737.
[74] Varghese C, Harrison EM, O'Grady G, Topol EJ. Artificial intelligence in surgery. Nat Med 2024;30(5):1257–1268. doi:10.1038/s41591-024-02970-3, PMID:38740998.
[75] Dundar TT, Yurtsever I, Pehlivanoglu MK, Yildiz U, Eker A, Demir MA, *et al*. Machine Learning-Based Surgical Planning for Neurosurgery: Artificial Intelligent Approaches to the Cranium. Front Surg 2022;9:863633. doi:10.3389/fsurg.2022.863633, PMID:35574559.
[76] Chinski H, Lerch R, Tournour D, Chinski L, Caruso D. An Artificial Intelligence Tool for Image Simulation in Rhinoplasty. Facial Plast Surg 2022;38(2):201–206. doi:10.1055/s-0041-1729911, PMID:34051703.
[77] Bari H, Wadhwani S, Dasari BVM. Role of artificial intelligence in hepatobiliary and pancreatic surgery. World J Gastrointest Surg 2021;13(1):7–18. doi:10.4240/wjgs.v13.i1.7, PMID:33552391.
[78] Wang DD, Qian Z, Vukicevic M, Engelhardt S, Kheradvar A, Zhang C, *et al*. 3D Printing, Computational Modeling, and Artificial Intelligence for Structural Heart Disease. JACC Cardiovasc Imaging 2021;14(1):41–60. doi:10.1016/j.jcmg.2019.12.022, PMID:32861647.
[79] Cheng K, Li Z, Guo Q, Sun Z, Wu H, Li C. Emergency surgery in the era of artificial intelligence: ChatGPT could be the doctor's right-hand man. Int J Surg 2023;109(6):1816–1818. doi:10.1097/JS9.0000000000000410, PMID:37074733.
[80] Ng MSP, Loke RWK, Tan MKL, Ng YH, Liau ZQG. The P Balasubramaniam Award-2024 Singapore Orthopaedic Association Annual Scientific Meeting Award: Novel artificial intelligence algorithm for soft tissue balancing and bone cuts in robotic total knee arthroplasty improves accuracy and surgical duration. Arthroplasty 2025;7(1):39. doi:10.1186/s42836-025-00322-1, PMID:40754533.
[81] Al Raeei M. Artificial intelligence in action: improving breast disease management through surgical robotics and remote monitoring. Med Clin Pract 2024;7(4):100470. doi:10.1016/j.mcpsp.2024.100470.
[82] Yip M, Salcudean S, Goldberg K, Althoefer K, Menciassi A, Opfermann JD, *et al*. Artificial intelligence meets medical robotics. Science 2023;381(6654):141–146. doi:10.1126/science.adj3312, PMID:37440630.
[83] Zrinscak D, Lorenzon L, Maselli M, Cianchetti M. Soft robotics for physical simulators, artificial organs and implantable assistive devices. Prog Biomed Eng (Bristol) 2023;5(1):012002. doi:10.1088/2516-1091/acb57a, PMID:41074855.
[84] Knudsen JE, Ghaffar U, Ma R, Hung AJ. Clinical applications of artificial intelligence in robotic surgery. J Robot Surg 2024;18(1):102. doi:10.1007/s11701-024-01867-0, PMID:38427094.
[85] Han J, Davids J, Ashrafian H, Darzi A, Elson DS, Sodergren M. A systematic review of robotic surgery: From supervised paradigms to fully autonomous robotic approaches. Int J Med Robot 2022;18(2):e2358. doi:10.1002/rcs.2358, PMID:34953033.
[86] Kim M, Zhang Y, Jin S. Soft tissue surgical robot for minimally invasive surgery: a review. Biomed Eng Lett 2023;13(4):561–569. doi:10.1007/s13534-023-00326-3, PMID:37872994.
[87] von Eisenhart-Rothe R, Hinterwimmer F, Graichen H, Hirschmann MT. Artificial intelligence and robotics in TKA surgery: promising options for improved outcomes? Knee Surg Sports Traumatol Arthrosc 2022;30(8):2535–2537. doi:10.1007/s00167-022-07035-x, PMID:35723703.
[88] Wendler T, van Leeuwen FWB, Navab N, van Oosterom MN. How molecular imaging will enable robotic precision surgery : The role of artificial intelligence, augmented reality, and navigation. Eur J Nucl Med Mol Imaging 2021;48(13):4201–4224. doi:10.1007/s00259-021-05445-6, PMID:34185136.
[89] Nwoye E, Woo WL, Gao B, Anyanwu T. Artificial Intelligence for Emerging Technology in Surgery: Systematic Review and Validation. IEEE Rev Biomed Eng 2023;16:241–259. doi:10.1109/RBME.2022.3183852, PMID:35709113.
[90] Panesar S, Cagle Y, Chander D, Morey J, Fernandez-Miranda J, Kliot M. Artificial Intelligence and the Future of Surgical Robotics. Ann Surg 2019;270(2):223–226. doi:10.1097/SLA.0000000000003262, PMID:30907754.
[91] Lin M, Hu H, Zhou S, Xu S. Soft wearable devices for deep tissue sensing. Nat Rev Mater 2022;7(11):850–869. doi:10.1038/s41578-022-00427-y.
[92] De Fazio R, Mastronardi VM, De Vittorio M, Visconti P. Wearable Sensors and Smart Devices to Monitor Rehabilitation Parameters and Sports Performance: An Overview. Sensors (Basel) 2023;23(4):1856. doi:10.3390/s23041856, PMID:36850453.
[93] Gonzalez Vazquez A, Garcia L, Kilby J, McNair P. Soft wearable rehabilitation robots with artificial muscles based on smart materials: a review. Adv Intell Syst 2023;5(4):2200159. doi:10.1002/aisy.202200159.
[94] Sartori M, Sawicki GS. Closing the loop between wearable technology and human biology: a new paradigm for steering neuromuscular form and function. Prog Biomed Eng 2021;3(2):023001. doi:10.1088/2516-1091/abe3e0.
[95] Al-Raeei M. The Future of Oral Oncology: How Artificial Intelligence is Redefining Surgical Procedures and Patient Management. Int Dent J 2025;75(1):109–116. doi:10.1016/j.identj.2024.09.032, PMID:39395899.
[96] Lurin IA, Khomenko IP, Nehoduiko VV, Tertyshnyi SV, Makarov VV, Kvasnevskyi IY, *et al*. Prospects of the high-speed multimedia data transmission technologies use in the structure of the system for providing aid to injured persons having a gunshot defect of soft tissues. Wiad Lek 2023;76(5 pt 2):1191–1198. doi:10.36740/WLek202305209, PMID:37364072.
[97] Al Raeei M. From diagnosis to treatment: the comprehensive integration of artificial intelligence in modern dental care. Curr Trends Dent 2025;2(1):13–17. doi:10.4103/CTD.CTD_4_25.
[98] Phuphanich ME, Sinha KR, Truong M, Pham QG. Telemedicine for Musculoskeletal Rehabilitation and Orthopedic Postoperative Rehabilitation. Phys Med Rehabil Clin N Am 2021;32(2):319–353. doi:10.1016/j.pmr.2020.12.004, PMID:33814061.
[99] Nyberg J, Hooker AC, Zimmermann G, Verbeeck J, Geroldinger M, Thiel KE, *et al*. Optimizing designs in clinical trials with an application in treatment of epidermolysis bullosa simplex, a rare genetic skin disease. Comput Stat Data Anal 2024;199:108015. doi:10.1016/j.csda.2024.108015.
[100] Chu CR, Rodeo S, Bhutani N, Goodrich LR, Huard J, Irrgang J, *et al*. Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg 2019;27(2):e50–e63. doi:10.5435/JAAOS-D-18-00305, PMID:30300216.
[101] Hayes AJ, Nixon IF, Strauss DC, Seddon BM, Desai A, Benson C, *et al*. UK guidelines for the management of soft tissue sarcomas. Br J Cancer 2025;132(1):11–31. doi:10.1038/s41416-024-02674-y, PMID:38734790.
[102] Bala I, Pindoo I, Mijwil MM, Abotaleb M, Yundong W. Ensuring security and privacy in healthcare systems: a review exploring challenges, solutions, future trends, and the practical applications of artificial intelligence. Jordan Med J 2024;58(3):250–270. doi:10.35516/jmj.v58i2.2527.
[103] Aquino YSJ, Carter SM, Houssami N, Braunack-Mayer A, Win KT, Degeling C, *et al*. Practical, epistemic and normative implications of algorithmic bias in healthcare artificial intelligence: a qualitative study of multidisciplinary expert perspectives. J Med Ethics 2025;51(6):420–428. doi:10.1136/jme-2022-108850, PMID:36823101.
[104] Hussain SA, Bresnahan M, Zhuang J. The bias algorithm: how AI in healthcare exacerbates ethnic and racial disparities - a scoping review. Ethn Health 2025;30(2):197–214. doi:10.1080/13557858.2024.2422848, PMID:39488857.
[105] Matsuzaki T. Ethical issues of artificial intelligence in medicine. Cal WL Rev 2018;55(1):7.
[106] Ibrahim AM, Zoromba MA, Abousoliman AD, Zaghamir DEF, Alenezi IN, Elsayed EA, *et al*. Ethical implications of artificial intelligence

integration in nursing practice in arab countries: literature review. BMC Nurs 2025;24(1):159. doi:10.1186/s12912-025-02798-3, PMID: 39934834.
[107] Al-Raeei M. Artificial intelligence and surgical robotics in the future of head-and-neck cancer care. Cancer Plus 2025. doi:10.36922/CP025040006.
[108] Lekadir K, Frangi AF, Porras AR, Glocker B, Cintas C, Langlotz CP, *et al*. FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare. BMJ 2025;388:e081554. doi:10.1136/bmj-2024-081554, PMID:39909534.
[109] Hanna MG, Pantanowitz L, Jackson B, Palmer O, Visweswaran S, Pantanowitz J, *et al*. Ethical and Bias Considerations in Artificial Intelligence/Machine Learning. Mod Pathol 2025;38(3):100686. doi:10.1016/j.modpat.2024.100686, PMID:39694331.